Status:
UNKNOWN
Radial Extracorporeal Shock Wave Therapy for Acute Hamstring Muscle Complex Injury Type 3b in Athletes
Lead Sponsor:
Kinef Kinesiología Deportiva
Collaborating Sponsors:
Ludwig-Maximilians - University of Munich
Conditions:
Athletic Injuries
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
This study tests the hypothesis that the combination of radial extracorporeal shock wave therapy performed with the Swiss DolorClast device (Electro Medical Systems, Nyon, Switzerland) and a specific ...
Detailed Description
Acute injuries of the hamstring muscle complex (HMC) are frequently observed in various sports disciplines both in elite and recreational sport, and are the most common injury in soccer. Despite inten...
Eligibility Criteria
Inclusion
- Adults (both male and female) with clinical and ultrasonographic diagnosis of acute HMC injury Type 3b
- Age range: between 18 and 35 years
- Physical conditions for rehabilitation (i.e., no surgery required)
- Willingness of the patient to participate in the study, and written informed consent signed and personally dated by the patient
- No contraindications for rESWT
Exclusion
- Children and teenagers below the age of 18
- Adults aged \>35 years old
- Patients with clinical and ultrasonographic diagnosis of acute HMC injury Type 3b who got injured more than seven days before potential enrollment into this study
- Patients with clinical and ultrasonographic diagnosis of acute HMC injury Type 3A or Type 4
- Bilateral acute HMC injury (Types 3A, 3B or 4)
- Proven or suspected HMC injury (Types 3A, 3B or 4) of the same lower limb in the time period of six months before potential enrollment into this study
- Muscle injury caused by external impact on the back of the affected thigh
- Surgery on the affected lower limb in the time period of one year before potential enrollment into this study
- Acute or chronic lumbar pathology (because some cases of thigh pain may relate to spinal pathology)
- No willingness of the patient to participate in this study, and/or written informed consent not signed and not personally dated by the patient
- Contraindications of rESWT, i.e., treatment of pregnant patients, treatment of patients with blood-clotting disorders (including local thrombosis), treatment of patients treated with oral anticoagulants, treatment of patients with local bacterial and/or viral infections/inflammations, treatment of patients with local tumors, and treatment of patients treated with local corticosteroid applications in the time period of six weeks before the first rESWT session (if applicable).
Key Trial Info
Start Date :
March 22 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03473899
Start Date
March 22 2018
End Date
October 1 2020
Last Update
March 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
KinEf Kinesiología Deportiva
Buenos Aires, Buenos Aires F.D., Argentina, 1426